Practitioner attitudes to clozapine initiation

Acta Psychiatrica Scandinavica

Volumn 130, Issue 1, 2014, Pages 16-24

  Gee, S ^a,b   Vergunst, F ^b,c   Howes, O ^b   Taylor, D ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antipsychotic agents; Physician's practice patterns; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADMINISTRATIVE PERSONNEL; ADULT; ARTICLE; BLOOD EXAMINATION; DAY HOSPITAL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE MANPOWER; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HOSPITAL ADMISSION; HUMAN; MALE; MEDICATION COMPLIANCE; NURSE; OCCUPATIONAL THERAPIST; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT WORRY; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOLOGIST; PSYCHOPHARMACOTHERAPY; QUESTIONNAIRE; SCHIZOPHRENIA; SOCIAL WORKER; TREATMENT REFUSAL; UNITED KINGDOM; ADOLESCENT; CLINICAL PRACTICE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CLOZAPINE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84902073226     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12193     Document Type: Article

References (68)

1. Claghorn J, Honigfeld G, Abuzzahab FS et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-384.
2. Essali A, Al-Haj N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;CD000059.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
4. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic - results of a US multicenter trial. Psychopharmacology 1989;99:S60-S63.
5. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725.
6. Covington L, Cola PA. Clozapine vs. Haloperidol: antipsychotic effects on sexual function in schizophrenia. Sex Disabil 2000;18:41-48.
7. Glazer W, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;50(Suppl 3):3-7.
8. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (INTERSEPT). Arch Gen Psychiatry 2003;60:82-91.
9. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia. Psychopharmacology 1989;99:S73-S76.
10. Casey DE. Effects of clozapine therapy in schizophrenia at risk for tardive dyskinesia. J Clin Psychiatry 1998;50(Suppl 3):3-7.
11. National Institute for Health and Clinical Excellence. Schizophrenia. London: National Institute for Health and Clinical Excellence, 2010.
12. Taylor D, Paton C, Kapur S. The maudsley prescribing guidelines in psychiatry, 11th edn. Chichester: Wiley-Blackwell, 2012.
13. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620.
14. Falkai P, Wobrock T, Lieberman J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5-40.
15. Noel JM. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm 2007;64:863-876.
16. Moore TS, Buchanan RW, Buckley PF et al. The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update. J Clin Psychiatry 2007;68:1751-1762.
17. Miller AL, Hall CS, Buchanan RW et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-508.
18. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005;187:248-255.
19. Meltzer HY, Cola P, Way L et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
20. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995;92:199-201.
21. Rosenheck R, Cramer J, Allan E et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch Gen Psychiatry 1999;56:565-572.
22. Rosenheck R, Cramer J, Xu W et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Serv Res 1998;33:1237-1261.
23. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia - clozapine related studies. J Clin Psychiatry 1999;60(Suppl 1):7-11.
24. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854.
25. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacol 2002;16:169-175.
26. Purcell H, Lewis S. Postcode prescribing in psychiatry: clozapine in an English county. Psychiatr Bull 2000;24:420-422.
27. Hayhurst KP, Brown P, Lewis SW. Postcode prescribing for schizophrenia. Br J Psychiatry 2003;182:281-283.
28. Downs J, Zinkler M. Clozapine: national review of postcode prescribing. Psychiatr Bull 2007;31:384-387.
29. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64:30-34.
30. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-485.
31. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995;46:801-806.
32. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22:15-25.
33. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of Switching Antipsychotic Medications. Am J Psychiatry 2006;163:2090-2095.
34. Rosenheck RA, Davis S, Covell N et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 2009;107:22-29.
35. Agid O, Arenovich T, Sajeev G et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011;72:1439-1444.
36. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia, a systematic review and meta-analysis of clinical trials. Am J Psychiatry 1999;156:990-999.
37. Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27:369-373.
38. Galletly CA, Clark CR, McFarlane AC, Weber DL. Effects of clozapine for non-treatment-resistant patients with schizophrenia. Psychiatr Serv 1999;50:101-103.
39. Lieberman JA, Phillips M, Gu H et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 2003;28:995-1003.
40. Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010;177:286-293.
41. Gaebel W, Riesbeck M, Janssen B et al. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions. Eur Arch Psychiatry Clin Neurosci 2003;253:175-184.
42. Wheeler AJ. Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand. Ann Pharmacother 2008;42:852-860.
43. Nielsen J, Røge R, Schjerning O, Sørensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol 2012;22:818-824.
44. Correll CU, Shaikh L, Gallego JA et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 2011;131:58-62.
45. Barley M, Pope C, Chilvers R, Sipos A, Harrison G. Guidelines or mindlines? A qualitative study exploring what knowledge informs psychiatrists decisions about antipsychotic prescribing. J Ment Health 2008;17:9-17.
46. Swinton M, Ahmed AG. Reasons for non-prescription of clozapine in treatment-resistant schizophrenia. Crim Behav Ment Health 1999;9:207-214.
47. O'Brien A, Firn M. Clozapine initiation in the community. Psychiatr Bull 2002;26:339-341.
48. O'Brien A. Starting clozapine in the community: a UK perspective. CNS Drugs. 2004;18:845-852.
49. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-971.
50. Taylor D, Shapland L, Laverick G, Bond J, Munro J. Clozapine - a survey of patient perceptions. Psychiatr Bull 2000;24:450-452.
51. Angermeyer MC, Loffler W, Muller P, Schulze B, Priebe S. Patients' and relatives' assessment of clozapine treatment. Psychol Med 2001;31:509-517.
52. Hodge K, Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. Int J Ment Health Nurs 2008;17:2-8.
53. Rosenheck R, Chang S, Choe Y et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-386.
54. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007;68:818-825.
55. Valevski A, Gilat Y, Olfson M, Benaroya-Milshtein N, Weizman A. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission. Int Clin Psychopharmacol 2012;27:159-164.
56. Hamann J, Mischo C, Langer B, Leucht S, Kissling W. Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophrenia. Psychiatr Serv 2005;56:1448-1450.
57. Weinmann S, Koesters M, Becker T. Effects of implementation of psychiatric guidelines on provider performance and patient outcome: systematic review. Acta Psychiatr Scand 2007;115:420-433.
58. Leucht S. Psychiatric treatment guidelines: doctor's non-compliance or insufficient evidence? Acta Psychiatr Scand 2007;115:417-419.
59. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003;33:83-89.
60. Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract 2009;15:441-450.
61. Paton C, Barnes TRE, Cavanagh M-R, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008;192:435-439.
62. Längle G, Steinert T, Weiser P et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 2012;125:372-381.
63. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2012; doi: 10.1017/S1461145712000399 [Epub ahead of print].
64. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-542.
65. Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 2012;125:349-351.
66. Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2011;72:194-204.
67. The Schizophrenia Commission. The abandoned illness. London: The Schizophrenia Commission, 2012.
68. Royal College of Psychiatrists. Report of the national audit of schizophrenia. London: Healthcare Quality Improvement Partnership, 2012.